<DOC>
	<DOCNO>NCT02976272</DOCNO>
	<brief_summary>Chemotherapy-induced peripheral neuropathy ( CIPN ) remain problem oncology `` gold standard '' treatment exist prevent treat CIPN . Therefore , oncologists reduce stop chemotherapy dose limit degradation quality life patient CIPN . Bortezomib relatively understudied neurotoxicity remain limiting factor treatment . Since 2012 , FDA EMA validate administration bortezomib subcutaneously ( SC ) instead intravenous ( IV ) order limit neurotoxicity . However , retrospective study report prevalence neuropathy induce bortezomib SC administration remain high equivalent IV route . No study quantitatively qualitatively evaluated sensory disorder peripheral neuropathy induce bortezomib SC administration . On hand , QLQ-CIPN20 questionnaire ( EORTC ) evaluate intensity sensory , motor autonomic disorder associate CIPN never test population . The objective study twofold : ( ) psychophysical evaluation neuropathic disorder study thermal vibratory detection threshold thermal nociceptive threshold ( ii ) quantitative qualitative assessment neuropathic disorder QLQ-CIPN20 related comorbidities population neuropathic patient treat bortezomib ( n = 15 ) , compare control patient treat bortezomib non-neuropathic ( n = 45 ) .</brief_summary>
	<brief_title>Neurotoxic Effect Bortezomib Treatment Patient With Myeloma Multiple</brief_title>
	<detailed_description>Peripheral neuropathy induce cancer chemotherapy ( CIPN ) remain problem oncology . These CIPN induce certain class chemotherapy taxanes ( paclitaxel docetaxel ) , platinum salt ( cisplatin oxaliplatin ) , alkaloids Madagascar periwinkle ( vincristine ) , bortezomib , thalidomide eribulin . These CIPN essentially result sensory disturbance paresthesia , dysesthesia numbness . Unfortunately , treatment offer `` gold standard '' prevent treat CIPN . Therefore , oncologists reduce stop dos chemotherapy patient suffer CIPN mark deterioration quality life suffer comorbidities anxiety , depression sleep disorder . Among chemotherapy , bortezomib remain relatively understudied term pathophysiology , compare platinum salt taxanes , whereas neurotoxicity bortezomib remain limiting factor treatment . Currently , bortezomib indicate treatment 1st line multiple myeloma follow protocol : - Patients &lt; 65 year : Protocol VTD : Velcade ( bortezomib ) , thalidomide , dexamethasone + autologous transplant - Patients &gt; 65 : Protocol MPV : Melphalan , Prednisone , Velcade . Or Protocol VD : Velcade , dexamethasone Since 2012 , FDA EMA validate subcutaneous administration bortezomib instead intravenously , order limit adverse effect bortezomib , include neurotoxicity . Indeed , large study report subcutaneous bortezomib allow keep therapeutic efficacy improve safety profile particular limit peripheral neuropathy ( CIPN grade : 38 % vs 53 % , grade ≥2 : 24 % vs 41 % , grade ≥3 6 % vs 16 % ) . However , recent retrospective study report prevalence peripheral neuropathy induce bortezomib subcutaneous administration remain relatively high : CIPN grade : 41 % , grade ≥2 : 18 % grade ≥3 : 4 % , especially prevalence CIPN different subcutaneous intravenous route . Bortezomib administer subcutaneously limit appearance neuropathic disorder study evaluate quantitatively qualitatively ( QST ) sensory disorder patient peripheral neuropathy induce bortezomib subcutaneous administration . On hand , measurement tool like QLQ-CIPN20 questionnaire ( EORTC ) evaluate intensity sensory , motor autonomic disorder associate CIPN never test patient population . While questionnaire present appropriate tool evaluation CIPN . Thus , exploration peripheral neuropathy induce bortezomib subcutaneous administration QST ( thermal ) QLQ-CIPN20 questionnaire would complement clinical knowledge CIPN . This knowledge essential propose test new strategy treatment prevention peripheral neuropathy induce bortezomib . The objective study twofold : ( ) psychophysical evaluation neuropathic disorder study QST ( thermal vibratory sensory threshold , thermal nociceptive threshold ) ( ii ) quantitative qualitative assessment neuropathic disorder QLQ -CIPN20 questionnaire ( EORTC ) associate comorbidities patient treat bortezomib ( subcutaneous administration ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Multiple myeloma diagnosis . Patient undergo receive bortezomibbased chemotherapy firstline ( VTD protocol , MPV VD ) . Case Group : peripheral sensory neuropathy Neuropathy ≥ grade 2 ( grade 23 ) NCICTCAE Control group : asymptomatic Neuropathy grade &lt; 2 ( grade 01 ) NCICTCAE Age &lt; 18 year . Treatment history neurotoxic chemotherapy ( taxanes , platinum salt , bortezomib , thalidomide , eribulin ) current treatment . Existing treatment : opioids , tricyclic antidepressant , pregabalin , gabapentin , duloxetine AEDs . Drinking : Male &gt; 3 Woman &gt; 2 unit per day . Peripheral neuropathy history know neuropathic pain Progressive neurological disease . Patient enrol clinical study evaluate preventive curative treatment chemotherapyinduced peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bortezomib regimen</keyword>
	<keyword>patient multiple myeloma</keyword>
</DOC>